Quick Takeaways Why It Matters? VMD Sciences is positioning itself as a supply-chain backup for large-animal practice, which matters because drug shortages can quickly disrupt equine colic care and other urgent treatments. The market implication is that it can win relevan...
Quick Takeaways Why It Matters? Medline’s move is a smart adjacency play: it brings a proven sterile-kitting model from human healthcare into animal health, where shelters and high-volume clinics care a lot about speed, consistency, and labor savings. The big ma...
Quick Takeaways Why It Matters? Gelteq’s animal health trial gives it a foothold in the large antiparasitic market and turns its gel-based platform into a potential formulation partner for veterinary pharma, not just nutraceuticals. If the data support a later FDA filing,...
Quick Takeaways Why It Matters? CosACTHen gives Dechra a differentiated diagnostic anchor in canine endocrinology and should strengthen its existing Cushing’s/Addison’s franchise built around Vetoryl. As the first and only FDA‑approved cosyntropin spec...
Quick Takeaways Why It Matters? This deal gives Viromed a faster route to commercialize PulmoPlas in veterinary respiratory care, starting with horses, while NEBU-TEC gets exclusive global distribution rights in that segment. The biggest market upside is in ...
Quick Takeaways Why It Matters? Piclidenoson could open a new, higher‑value segment in the canine osteoarthritis market as one of the first oral, potentially disease‑modifying options rather than just another pain reliever. If the ongoing Phase II trial confirms the posit...
Quick Takeaways Why It Matters? Liavium-CA1 gives Pegasus (PRN Pharmacal) a first-in-class, branded neurology asset in a completely underserved niche, which should support premium pricing and strong loyalty among neurologists and specialty practices that see CM/SM dogs. B...
Quick Takeaways Why It Matters? Befrena gives Elanco a direct challenger to Zoetis’ Cytopoint in the fast‑growing canine allergy biologics market, with a slightly longer recommended dosing interval (every 6–8 weeks vs 4–8 weeks) and no age or weight limits...
Quick Takeaways: Why It Matters? This launch is Yuyu Pharma’s first real step into the US pet health market, using Amazon as a low‑barrier, high‑visibility channel to test its cat wellness offering and build brand awareness under the Mervyn’s Petcare label. If Ari’s...
Quick Takeaways Why It Matters? VetSnap’s new 2‑Bay Smart Locker gives small and mobile veterinary practices a lower-cost way to get DEA‑compliant, automated storage and tracking for controlled drugs, instead of relying on basic safes and paper logs. By pricing...
